摘要
肺炎链球菌可能仍是社区获得性肺炎的主要致病菌，在针对肺炎链球菌肺炎的治疗中一直存在着是否应该联合用药、β-内酰胺类和大环内酯类抗菌药物能否联合应用的争议。从联合治疗对临床最终结果的影响、联合治疗的作用机制以及联合治疗可能带来的问题等方面综合近年的成年及儿童肺炎链球菌感染的临床研究与实验研究结果，提出了联合应用大环内酯类与β内酰胺类抗生素可能是一种减少重症肺炎链球菌感染进展、降低病死率与住院率的有效策略，但关于肺炎链球菌感染联合治疗的必要性仍未明确。
Streptococcus pneumoniae may be the commonest cause of the community acquired pneumonia （CAP）. However, the definitive decision regarding the need for combination antibiotic therapy for the effective management of pneumococcal infections has not yet been formally proved, also in the decision regarding the use of beta-lactam/macrolide combination. This review integrated recent studies about adults and children to help to make further understanding in these controversies from these aspects including the impact of the clinical final result, the mechanism of combination therapy and the potential problems with the combination therapy. The definitive decision regarding the need for combination antibiotic therapy for the effective management of pneumococcal infections has not yet been formally resolved.
出处
《国际儿科学杂志》
2011年第5期449-451,共3页
International Journal of Pediatrics
关键词
肺炎链球菌
抗生素
联合治疗
Streptococcus pneumoniae
Antibiotic
Combination therapy
